Dulaglutide: Who for and how to start?

WEBINAR: Wednesday 24 November 2021, 7.30 - 8.45 pm

Ryan Paul will present a practical guide around experiences with dulaglutide, the newly funded subcutaneous once weekly GLP1 receptor agonist for type 2 diabetes.

Key topics include:

  • Identifying which of your patients will benefit from dulaglutide.
  • Which patients meet the special authority criteria for dulaglutide and who should consider self-funding.
  • When to choose dulaglutide or empagliflozin or both.
  • How to discuss starting dulaglutide with patients and how to manage any adverse effects.
  • Recommended follow up for patients on dulaglutide.

As always, we will answer as many questions as we can as time permits.




Dr Ryan Paul

BHB MBChB (Auckland) FRACP, PhD

Ryan Paul is an endocrinologist and diabetologist at the Waikato District Health Board. He is active in research in his roles as a Senior Lecturer at the University of Waikato and as a Clinical Associate of the Maurice Wilkins Centre. He also has a key role in teaching as a member of the Royal Australasian College of Physicians (RACP) Training Committees and with Diabetes Nurse Prescribers in New Zealand, and was awarded the New Zealand Clinical Educator of the Year by the New Zealand Medical Council in 2019.

Ryan is also the current President of the New Zealand Society of Endocrinology (NZSE) and an Executive Member of the New Zealand Society for the Study of Diabetes (NZSSD). He recently convened the new NZSSD national guidance on the management of type 2 diabetes.


This webinar is supported by Lilly:

This presentation is intended for qualified health practitioners professional development and should not be relied upon for any other purpose. Any opinions offered are those of the presenter or other speaker and do not necessarily represent the views of Goodfellow Unit.

Sign into the website in order to register for this event.

Sign in